Stephen KL Chia
Stephen KL Chia
Verified email at
Cited by
Cited by
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ...
JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
SP Shah, A Roth, R Goya, A Oloumi, G Ha, Y Zhao, G Turashvili, J Ding, ...
Nature 486 (7403), 395-399, 2012
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
MCU Cheang, D Voduc, C Bajdik, S Leung, S McKinney, SK Chia, ...
Clinical cancer research 14 (5), 1368-1376, 2008
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive earlyá…
A Schneeweiss, S Chia, T Hickish, V Harvey, A Eniu, R Hegg, C Tausch, ...
Annals of oncology 24 (9), 2278-2284, 2013
Population-based validation of the prognostic model ADJUVANT! for early breast cancer
IA Olivotto, CD Bajdik, PM Ravdin, CH Speers, AJ Coldman, BD Norris, ...
Journal of Clinical Oncology 23 (12), 2716-2725, 2005
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women withá…
S Chia, W Gradishar, L Mauriac, J Bines, F Amant, M Federico, L Fein, ...
Journal of clinical oncology 26 (10), 1664-1670, 2008
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors
Y Lou, PC McDonald, A Oloumi, S Chia, C Ostlund, A Ahmadi, A Kyle, ...
Cancer research 71 (9), 3364-3376, 2011
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
P Eirew, A Steif, J Khattra, G Ha, D Yap, H Farahani, K Gelmon, S Chia, ...
Nature 518 (7539), 422-426, 2015
The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer
SK Chia, CH Speers, Y D'yachkova, A Kang, S Malfair‐Taylor, J Barnett, ...
Cancer 110 (5), 973-979, 2007
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
L Hughes-Davies, D Huntsman, M Ruas, F Fuks, J Bye, SF Chin, J Milner, ...
Cell 115 (5), 523-535, 2003
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma
SK Chia, CC Wykoff, PH Watson, C Han, RD Leek, J Pastorek, KC Gatter, ...
Journal of Clinical Oncology 19 (16), 3660-3668, 2001
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
J Clin Oncol 36 (24), 2465-2472, 2018
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3á…
A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ...
The Lancet Oncology 17 (3), 367-377, 2016
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers
S Chia, B Norris, C Speers, M Cheang, B Gilks, AM Gown, D Huntsman, ...
Journal of clinical oncology 26 (35), 5697-5704, 2008
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, doubleá…
J Baselga, SA Im, H Iwata, J CortÚs, M De Laurentiis, Z Jiang, CL Arteaga, ...
The Lancet Oncology 18 (7), 904-916, 2017
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163.
SL Ellard, M Clemons, KA Gelmon, B Norris, H Kennecke, S Chia, ...
Clin Oncol 27 (27), 4536-4541, 2009
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen
SK Chia, VH Bramwell, D Tu, LE Shepherd, S Jiang, T Vickery, E Mardis, ...
Clinical cancer research 18 (16), 4465-4472, 2012
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast
CC Wykoff, N Beasley, PH Watson, L Campo, SK Chia, R English, ...
The American journal of pathology 158 (3), 1011-1019, 2001
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
FP O’malley, S Chia, D Tu, LE Shepherd, MN Levine, VH Bramwell, ...
Journal of the National Cancer Institute 101 (9), 644-650, 2009
The system can't perform the operation now. Try again later.
Articles 1–20